<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31167919</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>17</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle><i>In Vitro</i> and <i>In Vivo</i> Inhibition of the Infectivity of Human Enterovirus 71 by a Sulfonated Food Azo Dye, Brilliant Black BN.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e00061-19</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00061-19</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD), a highly contagious disease in children, is caused by human enteroviruses, including enterovirus 71 (EV71), coxsackievirus A16 (CVA16), and coxsackievirus A6 (CVA6). Although HFMD is usually mild and self-limiting, EV71 infection occasionally leads to fatal neurological disorders. Currently, no commercial antiviral drugs for HFMD treatment are available. Here, numerous sulfonated azo dyes, widely used as food additives, were identified as having potent antiviral activities against human enteroviruses. Among them, brilliant black BN (E151) was able to inhibit all EV71, CVA16, and CVA6 strains tested. In rhabdomyosarcoma cells, the 50% inhibitory concentrations of the dye E151 for various strains of EV71 ranged from 2.39&#x2009;&#x3bc;M to 28.12&#x2009;&#x3bc;M, whereas its 50% cytotoxic concentration was 1,870&#x2009;&#x3bc;M. Food azo dyes, including E151, interacted with the vertex of the 5-fold axis of EV71 and prevented viral entry. Their efficacy in viral inhibition was regulated by amino acids at VP1-98, VP1-145, and/or VP1-246. Dye E151 not only prevented EV71 attachment but also eluted attached viruses in a concentration-dependent manner. Moreover, E151 inhibited the interaction between EV71 and its cellular uncoating factor cyclophilin A. <i>In vivo</i> studies demonstrated that E151 at a dose of 200&#x2009;mg/kg of body weight/day given on the initial 4 days of challenge protected AG129 mice challenged with 10&#xd7; the 50% lethal dose of wild-type EV71 isolates. Taken together, these data highlight E151 as a promising antiviral agent against EV71 infection.<b>IMPORTANCE</b> Human enterovirus 71 (EV71) is one of the causative agents of hand, foot, and mouth disease in children and is responsible for thousands of deaths in the past 20&#x2009;years. Food azo dyes have been widely used since the nineteenth century; however, their biological effects on humans and microbes residing in humans are poorly understood. Here, we discovered that one of these dyes, brilliant black BN (E151), was particularly effective in inhibiting the infectivity of EV71 in both cell culture and mouse model studies. Mechanistic studies demonstrated that these sulfonated dyes mainly competed with EV71 attachment factors for viral binding to block viral attachment/entry to host cells. As no commercial antiviral drugs against EV71 are currently available, our findings open an avenue to exploit the development of permitted food dye E151 as a potential anti-EV71 agent.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Temasek Life Sciences Laboratory, Limited, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singapore, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Temasek Life Sciences Laboratory, Limited, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Sek-Man</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Temasek Life Sciences Laboratory, Limited, Singapore, Republic of Singapore dbswsm@nus.edu.sg chuakb@tll.org.sg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singapore, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NUS Suzhou Research Institute, Suzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Kaw-Bing</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Temasek Life Sciences Laboratory, Limited, Singapore, Republic of Singapore dbswsm@nus.edu.sg chuakb@tll.org.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001391">Azo Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005503">Food Additives</NameOfSubstance></Chemical><Chemical><RegistryNumber>2WPR32U0CP</RegistryNumber><NameOfSubstance UI="C000298">brilliant black 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber><NameOfSubstance UI="D021984">Cyclophilin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001391" MajorTopicYN="N">Azo Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021984" MajorTopicYN="N">Cyclophilin A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005503" MajorTopicYN="N">Food Additives</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AG129 mouse</Keyword><Keyword MajorTopicYN="N">antiviral agent</Keyword><Keyword MajorTopicYN="N">food azo dye</Keyword><Keyword MajorTopicYN="N">hand foot and mouth disease</Keyword><Keyword MajorTopicYN="N">human enterovirus</Keyword><Keyword MajorTopicYN="N">sulfonate</Keyword><Keyword MajorTopicYN="N">virus attachment factors</Keyword><Keyword MajorTopicYN="N">virus entry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31167919</ArticleId><ArticleId IdType="pmc">PMC6694806</ArticleId><ArticleId IdType="doi">10.1128/JVI.00061-19</ArticleId><ArticleId IdType="pii">JVI.00061-19</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S, Gacheva M, Mitov G, Ninov N, Tsylka E, Robinson I, Frolova M, Bashkirtsev V, Martiyanova L, Rodin V. 1979. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 60:329&#x2013;340. doi:10.1007/BF01317504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01317504</ArticleId><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778&#x2013;790. doi:10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, Lee CY. 1999. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354:1682&#x2013;1686. doi:10.1016/S0140-6736(99)04434-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Utama A, Yoshii K, Yoshida H, Yoneyama T, Sinniah M, Yusof MA, Okuno Y, Okabe N, Shih SR, Chen HY, Wang GR, Kao CL, Chang KS, Miyamura T, Hagiwara A. 1999. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J Infect Dis 52:12&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10808253</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Stratov I, Nagarajan L, Davis S. 2001. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32:236&#x2013;242. doi:10.1086/318454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318454</ArticleId><ArticleId IdType="pubmed">11170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JM, Wang JN, Tsai YC, Liu CC, Huang CC, Chen YJ, Yeh TF. 2002. Cardiopulmonary manifestations of fulminant enterovirus 71 infection. Pediatrics 109:E26. doi:10.1542/peds.109.2.e26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.109.2.e26</ArticleId><ArticleId IdType="pubmed">11826236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VT. 2010. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 14:e1076&#x2013;e1081. doi:10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J, Qi J. 2009. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 47:2351&#x2013;2352. doi:10.1128/JCM.00563-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00563-09</ArticleId><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL. 2013. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381:2024&#x2013;2032. doi:10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC. 2016. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev Vaccines 15:803&#x2013;813. doi:10.1080/14760584.2016.1191357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2016.1191357</ArticleId><ArticleId IdType="pubmed">27206811</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. doi:10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424&#x2013;429. doi:10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15:798&#x2013;801. doi:10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang M, Wang X, Wang Q, Wang Y, Lin J, Sun Y, Li X, Zhang L, Lou Z, Wang J, Rao Z. 2014. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell 5:692&#x2013;703. doi:10.1007/s13238-014-0087-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0087-3</ArticleId><ArticleId IdType="pmc">PMC4145081</ArticleId><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15:794. doi:10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Wakita T, Shimizu H. 2010. Tyrosine sulfation of the amino terminus of PSGL-1 is critical for enterovirus 71 infection. PLoS Pathog 6:e1001174. doi:10.1371/journal.ppat.1001174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001174</ArticleId><ArticleId IdType="pmc">PMC2973824</ArticleId><ArticleId IdType="pubmed">21079683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, Shimizu H. 2013. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog 9:e1003511. doi:10.1371/journal.ppat.1003511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003511</ArticleId><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar HR, Poh CL, Fecondo J, Grollo L. 2012. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against enterovirus 71. Virus Res 169:22&#x2013;29. doi:10.1016/j.virusres.2012.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611&#x2013;620. doi:10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Sam IC, Lee VS, Wong HV, Chan YF. 2017. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501:79&#x2013;87. doi:10.1016/j.virol.2016.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.11.009</ArticleId><ArticleId IdType="pubmed">27875780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Qing J, Sun Y, Rao Z. 2014. Suramin inhibits EV71 infection. Antiviral Res 103:1&#x2013;6. doi:10.1016/j.antiviral.2013.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.008</ArticleId><ArticleId IdType="pubmed">24374150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P, Zou G, Bailly B, Xu S, Zeng M, Chen X, Shen L, Zhang Y, Guillon P, Arenzana-Seisdedos F, Buchy P, Li J, von Itzstein M, Li Q, Altmeyer R. 2014. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection&#x2014;suramin inhibits EV71 infection in vitro and in vivo. Emerg Microbes Infect 3:e62. doi:10.1038/emi.2014.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.60</ArticleId><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, McLaughlin NP, Pan J, Goldstein S, Hafenstein S, Shimizu H, Winkler JD, Bergelson JM. 2015. The suramin derivative NF449 interacts with the 5-fold vertex of the enterovirus A71 capsid to prevent virus attachment to PSGL-1 and heparan sulfate. PLoS Pathog 11:e1005184. doi:10.1371/journal.ppat.1005184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005184</ArticleId><ArticleId IdType="pmc">PMC4592248</ArticleId><ArticleId IdType="pubmed">26430888</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J, Wang Y, Sun Y, Huang J, Yan W, Wang J, Su D, Ni C, Li J, Rao Z, Liu L, Lou Z. 2014. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog 10:e1004422. doi:10.1371/journal.ppat.1004422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Cifuente JO, Ashley RE, Conway JF, Makhov AM, Tano Y, Shimizu H, Nishimura Y, Hafenstein S. 2013. A strain-specific epitope of enterovirus 71 identified by cryo-electron microscopy of the complex with Fab from neutralizing antibody. J Virol 87:11363&#x2013;11370. doi:10.1128/JVI.01926-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01926-13</ArticleId><ArticleId IdType="pmc">PMC3807339</ArticleId><ArticleId IdType="pubmed">23946455</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Li G, Wang Y, Gao Q, Wang Y, Cui R, Altmeyer R, Zou G. 2016. Identification of positively charged residues in enterovirus 71 capsid protein VP1 essential for production of infectious particles. J Virol 90:741&#x2013;752. doi:10.1128/JVI.02482-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02482-15</ArticleId><ArticleId IdType="pmc">PMC4702679</ArticleId><ArticleId IdType="pubmed">26512078</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollinger H. 2003. Color chemistry: synthesis, properties, and applications of organic dyes and pigments, 3rd ed Wiley-VCH GmbH &amp; Co. KGaA, Weinheim, Germany.</Citation></Reference><Reference><Citation>Robinson T, McMullan G, Marchant R, Nigam P. 2001. Remediation of dyes in textile effluent: a critical review on current treatment technologies with a proposed alternative. Bioresour Technol 77:247&#x2013;255. doi:10.1016/S0960-8524(00)00080-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-8524(00)00080-8</ArticleId><ArticleId IdType="pubmed">11272011</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M, Schols D, Mohan P, De Clercq E, Shigeta S. 1993. Inhibition of HIV-1-induced cytopathogenicity, syncytium formation, and virus-cell binding by naphthalenedisulfonic acids through interaction with the viral envelope gp120 glycoprotein. Antivir Chem Chemother 4:229&#x2013;234. doi:10.1177/095632029300400405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/095632029300400405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojala WH, Ojala CR, Gleason WB. 1995. The X-ray crystal structure of the sulfonated azo dye Congo red, a non-peptidic inhibitor of HIV-1 protease which also binds to reverse transcriptase and amyloid proteins. Antivir Chem Chemother 6:25&#x2013;33. doi:10.1177/095632029500600104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/095632029500600104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojala WH, Sudbeck EA, Lu LK, Richardson TI, Lovrien RE, Gleason WB. 1996. Complexes of lysine, histidine, and arginine with sulfonated azo dyes: model systems for understanding the biomolecular recognition of glycosaminoglycans by proteins. J Am Chem Soc 118:2131&#x2013;2142. doi:10.1021/ja951121f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja951121f</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono M, Wada Y, Wu Y, Nemori R, Jinbo Y, Wang H, Lo KM, Yamaguchi N, Brunkhorst B, Otomo H, Wesolowski J, Way JC, Itoh I, Gillies S, Chen LB. 1997. FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes. Nat Biotechnol 15:343&#x2013;348. doi:10.1038/nbt0497-343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt0497-343</ArticleId><ArticleId IdType="pubmed">9094135</ArticleId></ArticleIdList></Reference><Reference><Citation>Weglarz TE, Gorecki L. 2012. Azo dyes&#x2014;biological activity and synthetic strategy. Chemik 66:1303&#x2013;1307.</Citation></Reference><Reference><Citation>Meng T, Kiener TK, Kwang J. 2012. RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production. Virol J 9:238. doi:10.1186/1743-422X-9-238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-238</ArticleId><ArticleId IdType="pmc">PMC3493273</ArticleId><ArticleId IdType="pubmed">23072515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang ML, Kiener TK, Lim XF, Kwang J. 2012. Identification and characterization of a monoclonal antibody recognizing the linear epitope RVADVI on VP1 protein of enterovirus 71. J Med Virol 84:1620&#x2013;1627. doi:10.1002/jmv.23372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23372</ArticleId><ArticleId IdType="pubmed">22930511</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86:2121&#x2013;2131. doi:10.1128/JVI.06103-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov DS. 2004. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2:109&#x2013;122. doi:10.1038/nrmicro817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro817</ArticleId><ArticleId IdType="pmc">PMC7097642</ArticleId><ArticleId IdType="pubmed">15043007</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Xu M, Yin Z. 2013. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res 97:183&#x2013;194. doi:10.1016/j.antiviral.2012.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.005</ArticleId><ArticleId IdType="pubmed">23261847</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Lai JK, Sam IC, Chan YF. 2014. Recent developments in antiviral agents against enterovirus 71 infection. J Biomed Sci 21:14. doi:10.1186/1423-0127-21-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-21-14</ArticleId><ArticleId IdType="pmc">PMC3924904</ArticleId><ArticleId IdType="pubmed">24521134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Shi J, Wang X, Liu Q, Huang Z. 2015. Single neutralizing monoclonal antibodies targeting the VP1 GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry. J Virol 89:12084&#x2013;12095. doi:10.1128/JVI.02189-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02189-15</ArticleId><ArticleId IdType="pmc">PMC4645313</ArticleId><ArticleId IdType="pubmed">26401034</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Fu C, Wu S, Chen X, Shi Y, Zhou B, Zhang L, Zhang F, Wang Z, Zhang Y, Fan C, Han S, Yin J, Peng B, Liu W, He X. 2014. A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China. Virus Genes 48:260&#x2013;272. doi:10.1007/s11262-014-1035-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-014-1035-2</ArticleId><ArticleId IdType="pubmed">24442718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Wu X, Huang K, Li L, Zheng L, Wan C, He ML, Zhao W. 2014. The variations of VP1 protein might be associated with nervous system symptoms caused by enterovirus 71 infection. BMC Infect Dis 14:243. doi:10.1186/1471-2334-14-243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-243</ArticleId><ArticleId IdType="pmc">PMC4101859</ArticleId><ArticleId IdType="pubmed">24886383</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Wang YF, Yu CK, Su IJ, Wang JR. 2012. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 422:132&#x2013;143. doi:10.1016/j.virol.2011.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.10.015</ArticleId><ArticleId IdType="pubmed">22078110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka C, Suzuki T, Kotani O, Iwata-Yoshikawa N, Nagata N, Ami Y, Wakita T, Nishimura Y, Shimizu H. 2015. The role of VP1 amino acid residue 145 of enterovirus 71 in viral fitness and pathogenesis in a cynomolgus monkey model. PLoS Pathog 11:e1005033. doi:10.1371/journal.ppat.1005033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005033</ArticleId><ArticleId IdType="pmc">PMC4504482</ArticleId><ArticleId IdType="pubmed">26181772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Sudaka Y, Takashino A, Imura A, Fujii K, Koike S. 2018. Amino acid variation at VP1-145 of enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice. J Virol 92:e00681-18. doi:10.1128/JVI.00681-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00681-18</ArticleId><ArticleId IdType="pmc">PMC6052303</ArticleId><ArticleId IdType="pubmed">29848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Sudaka Y, Takashino A, Kobayashi K, Kataoka C, Suzuki T, Iwata-Yoshikawa N, Kotani O, Ami Y, Shimizu H, Nagata N, Mizuta K, Matsuzaki Y, Koike S. 2018. VP1 amino acid residue 145 of enterovirus 71 is a key residue for its receptor attachment and resistance to neutralizing antibody during cynomolgus monkey infection. J Virol 92:e00682-18. doi:10.1128/JVI.00682-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00682-18</ArticleId><ArticleId IdType="pmc">PMC6052295</ArticleId><ArticleId IdType="pubmed">29848582</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Moncla LH, Ronderos MD, Friedrich TC, Osorio JE. 2016. A single mutation in the VP1 of enterovirus 71 is responsible for increased virulence and neurotropism in adult interferon-deficient mice. J Virol 90:8592&#x2013;8604. doi:10.1128/JVI.01370-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01370-16</ArticleId><ArticleId IdType="pmc">PMC5021399</ArticleId><ArticleId IdType="pubmed">27440896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P, Zheng Y, Wang W, Hong L, Delpeyroux F, Arenzana-Seisdedos F, Altmeyer R. 2017. Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A. Sci Rep 7:42902. doi:10.1038/srep42902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42902</ArticleId><ArticleId IdType="pmc">PMC5317167</ArticleId><ArticleId IdType="pubmed">28218309</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, Takebe Y, Pybus OG. 2010. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 84:3339&#x2013;3350. doi:10.1128/JVI.01019-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01019-09</ArticleId><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). 2010. Scientific Opinion on the re-evaluation of Brilliant Black BN (E 151) as a food additive on request from the European Commission. EFSA J 8:1540. doi:10.2903/j.efsa.2010.1540.</Citation><ArticleIdList><ArticleId IdType="doi">10.2903/j.efsa.2010.1540</ArticleId></ArticleIdList></Reference><Reference><Citation>Macioszek VK, Kononowicz AK. 2004. The evaluation of the genotoxicity of two commonly used food colors: quinoline yellow (E 104) and brilliant black BN (E 151). Cell Mol Biol Lett 9:107&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048155</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin KA, Abdel Hameid H 2nd, Abd Elsttar AH. 2010. Effect of food azo dyes tartrazine and carmoisine on biochemical parameters related to renal, hepatic function and oxidative stress biomarkers in young male rats. Food Chem Toxicol 48:2994&#x2013;2999. doi:10.1016/j.fct.2010.07.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2010.07.039</ArticleId><ArticleId IdType="pubmed">20678534</ArticleId></ArticleIdList></Reference><Reference><Citation>EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). 2010. Scientific opinion on the appropriateness of the food azo-colours Tartrazine (E 102), Sunset Yellow FCF (E 110), Carmoisine (E 122), Amaranth (E 123), Ponceau 4R (E 124), Allura Red AC (E 129), Brilliant Black BN (E 151), Brown FK (E 154), Brown HT (E 155) and Litholrubine BK (E 180) for inclusion in the list of food ingredients set up in Annex IIIa of Directive 2000/13/EC. EFSA J 8:1778. doi:10.2903/j.efsa.2010.1778.</Citation><ArticleIdList><ArticleId IdType="doi">10.2903/j.efsa.2010.1778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>